Diagnosis and Management of Infantile Hemangiomas in the Neonate

Nicole Harter, Anthony J Mancini

Research output: Contribution to journalReview article

Abstract

Infantile hemangiomas (IH) are a common benign tumor of infancy, most being uncomplicated and not requiring therapy. Some IH may require treatment; the pediatric provider must be familiar with morphology, distribution, natural history, and associations of IH. Several treatment options are available for IH: current standard of care, oral propranolol. Other therapies include wound care; topical beta-blocker therapy for small, superficial, and uncomplicated IH; treatment of IH residua. In addition to functional compromise and other complications, potential for permanent deformity and eventual psychosocial stigmatization are important when considering the need for treatment of IH in a neonate or infant.

Original languageEnglish (US)
Pages (from-to)437-459
Number of pages23
JournalPediatric Clinics of North America
Volume66
Issue number2
DOIs
StatePublished - Apr 1 2019

Fingerprint

Hemangioma
Newborn Infant
Therapeutics
Stereotyping
Standard of Care
Natural History
Propranolol
Pediatrics
Wounds and Injuries
Neoplasms

Keywords

  • Infantile hemangioma
  • Neonate
  • PHACE
  • Propranolol
  • Timolol

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

@article{7475aace4219472b87b851816fbd3388,
title = "Diagnosis and Management of Infantile Hemangiomas in the Neonate",
abstract = "Infantile hemangiomas (IH) are a common benign tumor of infancy, most being uncomplicated and not requiring therapy. Some IH may require treatment; the pediatric provider must be familiar with morphology, distribution, natural history, and associations of IH. Several treatment options are available for IH: current standard of care, oral propranolol. Other therapies include wound care; topical beta-blocker therapy for small, superficial, and uncomplicated IH; treatment of IH residua. In addition to functional compromise and other complications, potential for permanent deformity and eventual psychosocial stigmatization are important when considering the need for treatment of IH in a neonate or infant.",
keywords = "Infantile hemangioma, Neonate, PHACE, Propranolol, Timolol",
author = "Nicole Harter and Mancini, {Anthony J}",
year = "2019",
month = "4",
day = "1",
doi = "10.1016/j.pcl.2018.12.011",
language = "English (US)",
volume = "66",
pages = "437--459",
journal = "Pediatric Clinics of North America",
issn = "0031-3955",
publisher = "W.B. Saunders Ltd",
number = "2",

}

Diagnosis and Management of Infantile Hemangiomas in the Neonate. / Harter, Nicole; Mancini, Anthony J.

In: Pediatric Clinics of North America, Vol. 66, No. 2, 01.04.2019, p. 437-459.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Diagnosis and Management of Infantile Hemangiomas in the Neonate

AU - Harter, Nicole

AU - Mancini, Anthony J

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Infantile hemangiomas (IH) are a common benign tumor of infancy, most being uncomplicated and not requiring therapy. Some IH may require treatment; the pediatric provider must be familiar with morphology, distribution, natural history, and associations of IH. Several treatment options are available for IH: current standard of care, oral propranolol. Other therapies include wound care; topical beta-blocker therapy for small, superficial, and uncomplicated IH; treatment of IH residua. In addition to functional compromise and other complications, potential for permanent deformity and eventual psychosocial stigmatization are important when considering the need for treatment of IH in a neonate or infant.

AB - Infantile hemangiomas (IH) are a common benign tumor of infancy, most being uncomplicated and not requiring therapy. Some IH may require treatment; the pediatric provider must be familiar with morphology, distribution, natural history, and associations of IH. Several treatment options are available for IH: current standard of care, oral propranolol. Other therapies include wound care; topical beta-blocker therapy for small, superficial, and uncomplicated IH; treatment of IH residua. In addition to functional compromise and other complications, potential for permanent deformity and eventual psychosocial stigmatization are important when considering the need for treatment of IH in a neonate or infant.

KW - Infantile hemangioma

KW - Neonate

KW - PHACE

KW - Propranolol

KW - Timolol

UR - http://www.scopus.com/inward/record.url?scp=85061923775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061923775&partnerID=8YFLogxK

U2 - 10.1016/j.pcl.2018.12.011

DO - 10.1016/j.pcl.2018.12.011

M3 - Review article

VL - 66

SP - 437

EP - 459

JO - Pediatric Clinics of North America

JF - Pediatric Clinics of North America

SN - 0031-3955

IS - 2

ER -